Overview

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Status:
Completed

Trial end date:
2019-04-09

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

Phase:

Phase 3

Details

Lead Sponsor:

Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.

Treatments:

Parathyroid Hormone